SINOPHARM (01099.HK): Nine-Month Revenue RMB427.6bn, Net Profit Attributable RMB5.31bn

NewTimeSpace News: On 23 October 2026, Sinopharm Group Co. Ltd. (stock code: 01099) announced that, under the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, it published its unaudited financial information for the nine months ended 30 September 2026, prepared under PRC accounting standards, comprising the consolidated and company-level balance sheets, income statements and cash flow statements.

Revenue amounted to RMB427.613 billion, down about 0.89% from RMB431.479 billion a year earlier; cost of sales was RMB397.734 billion; net profit was RMB8.080 billion, down about 0.29%; net profit attributable to owners of the parent was RMB5.314 billion, up about 0.13%; and basic earnings per share were RMB1.70, unchanged from a year earlier.

As at 30 September 2026, total assets were RMB407.873 billion and total liabilities RMB268.602 billion, with total equity of RMB139.271 billion, of which RMB87.239 billion was attributable to owners of the parent and RMB52.031 billion to non-controlling interests. Major items included cash and cash equivalents of RMB37.833 billion, accounts receivable of RMB228.284 billion, inventories of RMB67.835 billion, short-term borrowings of RMB66.825 billion and accounts payable of RMB124.450 billion.

Net cash used in operating activities for the nine months was RMB23.935 billion, compared with RMB39.077 billion a year earlier, and the closing balance of cash and cash equivalents was RMB26.489 billion. The financial information is unaudited.